Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE-718 in Huntington's Disease (DIMENSION)
NCT05107128Phase 2Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Jan 2022
- Primary completion
- Sep 2024
- Modality
- Allosteric Modulators, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 4
01
Overview
A Phase 2 trial of dalzanemdor in Huntington's disease (HD), sponsored by Supernus Pharmaceuticals, Inc.. Started Jan 2022; status: completed.
02
Drugs
dalzanemdor
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT05107128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05107128.